Recruiting

ACT & Compassion-Based Therapy

Sponsor:

Mayo Clinic

Code:

NCT06246955

Conditions

Hematopoietic and Lymphoid System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Behavioral Intervention: Group Therapy Session

Survey Administration

Study Details

Brief summary:

This clinical trial tests how well acceptance and commitment therapy and compassion based virtual group therapy works to improve psychological wellbeing, such as compassion, understanding, and flexibility, in patients with cancer. Receiving a cancer diagnosis, undergoing cancer treatment, and living with cancer- or treatment-related symptoms have often been found to be associated with elevated distress and decreased quality of life for individuals, even when the disease is stable or in remission. Acceptance and Commitment Therapy (ACT) has demonstrated considerable benefits on individuals' quality of life, psychological flexibility, and amelioration of psychological distress following a cancer diagnosis and in the face of uncertainty, loss, and challenges associated with cancer.

Conditions

Hematopoietic and Lymphoid System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT06246955

Start date

Jan 8, 2024

Status verified date

May, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Being an adult (18 years or older)
  • Being a patient of Mayo Clinic Arizona
  • Having a cancer diagnosis, having treatment planning in progress, undergoing cancer-related treatment, or having completed cancer within the past 2 years (in recent survivorship
  • Experiencing stress or challenges related to cancer and having treatment goals that align with the purpose of the group
  • Having self reported proficiency to read/write/speak English
  • Expressing interest and commitment to attend all six virtual group sessions

Exclusion Criteria:

  • Patients' inability to take part in and benefit from the virtual group therapy based on clinical judgment of the psychosocial oncology team member who completes the psychosocial evaluation, which may include having active suicidal or homicidal intent, experiencing uncontrolled psychotic symptoms, having untreated personality disorder/characteristics that are likely disturbing in a group setting, and/or having moderate to severe cognitive impairments

Study Design

Enrollment

200 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Supportive care (group therapy sessions)

Patients attend acceptance and commitment virtual group therapy sessions over 1.5 hours each, once a week for 6 weeks.

Interventions

Behavioral Intervention: Group Therapy Session

Attend virtual group therapy sessions

Survey Administration

Ancillary study

Primary outcome measure

  • Participant perceived compassion and understanding by the group therapy provider - SCQ [ Time Frame: From baseline to 1 month post session 6 ]
  • Patients' self-reported psychological flexibility - COMPACT-15 [ Time Frame: From baseline to 1 month post session 6 ]
  • Patients' self-reported psychological flexibility - Psy-Flex [ Time Frame: From baseline to 1 month post session 6 ]
  • Physician and psychological distress - PROMIS-29 [ Time Frame: From baseline to 1 month post session 6 ]

Central Contacts and Locations

Central contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Locations

Mayo Clinic in Arizona

Recruiting

Scottsdale, Arizona, United States, 85259

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

Chun Tao, PhD, LP

More Information

Sponsor

Mayo Clinic

Last update posted

May 29, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-05-29.